TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from JBM (Healthcare) Ltd. ( (HK:2161) ).
JBM (Healthcare) Limited reported a significant financial performance for the six months ended 30 September 2025, with a 7.7% increase in revenue to approximately HK$429.6 million and a 23.8% rise in profit from operations to about HK$150.6 million compared to the same period in 2024. The company declared an interim dividend of HK9.75 cents per ordinary share, marking a 77.3% increase from the previous year, reflecting strong operational growth and a positive outlook for shareholders.
The most recent analyst rating on (HK:2161) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on JBM (Healthcare) Ltd. stock, see the HK:2161 Stock Forecast page.
More about JBM (Healthcare) Ltd.
JBM (Healthcare) Limited is a company incorporated in the Cayman Islands, operating within the healthcare industry. The company focuses on providing healthcare products and services, with its shares listed on the Stock Exchange of Hong Kong.
Average Trading Volume: 657,392
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.34B
See more insights into 2161 stock on TipRanks’ Stock Analysis page.